Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ABEO's Cash-to-Debt is ranked higher than
98% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ABEO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ABEO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.19 Max: No Debt
Current: No Debt
0.03
No Debt
Equity-to-Asset 0.97
ABEO's Equity-to-Asset is ranked higher than
98% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ABEO: 0.97 )
Ranked among companies with meaningful Equity-to-Asset only.
ABEO' s Equity-to-Asset Range Over the Past 10 Years
Min: -118.34  Med: -0.15 Max: 0.97
Current: 0.97
-118.34
0.97
Piotroski F-Score: 4
Altman Z-Score: 59.83
Beneish M-Score: 1.13
WACC vs ROIC
8.29%
-99.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -902.16
ABEO's Operating Margin % is ranked lower than
76% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. ABEO: -902.16 )
Ranked among companies with meaningful Operating Margin % only.
ABEO' s Operating Margin % Range Over the Past 10 Years
Min: -10560.48  Med: -1697.98 Max: -98
Current: -902.16
-10560.48
-98
Net Margin % -881.75
ABEO's Net Margin % is ranked lower than
76% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. ABEO: -881.75 )
Ranked among companies with meaningful Net Margin % only.
ABEO' s Net Margin % Range Over the Past 10 Years
Min: -10801.03  Med: -2013.67 Max: 217.87
Current: -881.75
-10801.03
217.87
ROE % -25.00
ABEO's ROE % is ranked higher than
61% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ABEO: -25.00 )
Ranked among companies with meaningful ROE % only.
ABEO' s ROE % Range Over the Past 10 Years
Min: -40.05  Med: -26.22 Max: -20.3
Current: -25
-40.05
-20.3
ROA % -23.80
ABEO's ROA % is ranked higher than
60% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ABEO: -23.80 )
Ranked among companies with meaningful ROA % only.
ABEO' s ROA % Range Over the Past 10 Years
Min: -602.71  Med: -92.96 Max: 379.77
Current: -23.8
-602.71
379.77
ROC (Joel Greenblatt) % -1087.42
ABEO's ROC (Joel Greenblatt) % is ranked lower than
67% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ABEO: -1087.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABEO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -523920  Med: -10774.8 Max: 72738.46
Current: -1087.42
-523920
72738.46
3-Year Revenue Growth Rate -65.20
ABEO's 3-Year Revenue Growth Rate is ranked lower than
87% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ABEO: -65.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABEO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -73.3 Max: 198.1
Current: -65.2
0
198.1
3-Year EBITDA Growth Rate 63.80
ABEO's 3-Year EBITDA Growth Rate is ranked higher than
97% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. ABEO: 63.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABEO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.3 Max: 70.5
Current: 63.8
0
70.5
3-Year EPS without NRI Growth Rate 64.90
ABEO's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ABEO: 64.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABEO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.1 Max: 72.7
Current: 64.9
0
72.7
GuruFocus has detected 3 Warning Signs with Abeona Therapeutics Inc ABEO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABEO's 30-Y Financials

Financials (Next Earnings Date: 2018-11-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ABEO Guru Trades in Q3 2017

Andreas Halvorsen 2,238,720 sh (New)
Steven Cohen 206,857 sh (New)
Paul Tudor Jones 32,108 sh (New)
George Soros Sold Out
Chuck Royce 227,221 sh (-27.22%)
Louis Moore Bacon 25,000 sh (-75.00%)
» More
Q4 2017

ABEO Guru Trades in Q4 2017

Louis Moore Bacon 100,000 sh (+300.00%)
Andreas Halvorsen 4,040,727 sh (+80.49%)
Steven Cohen 157,800 sh (-23.72%)
Chuck Royce 142,221 sh (-37.41%)
Paul Tudor Jones 12,108 sh (-62.29%)
» More
Q1 2018

ABEO Guru Trades in Q1 2018

Chuck Royce 142,221 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
Andreas Halvorsen 3,228,708 sh (-20.10%)
» More
Q2 2018

ABEO Guru Trades in Q2 2018

Chuck Royce 142,221 sh (unchged)
Andreas Halvorsen 2,550,741 sh (-21.00%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ABEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-09-30 Sold Out 0.13%$6.6 - $17.2 $ 12.6318%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2834
Compare:ROCO:4105, TPE:6541, SZSE:300497, NAS:AMRN, NAS:LXRX, XKRX:102940, XKRX:096530, NAS:ARMO, OSTO:RECI B, NAS:NTLA, NAS:URGN, SZSE:000518, SZSE:300147, TSE:2931, OCSE:BAVA, XSWX:BSLN, XPAR:GNFT, BOM:540701, SZSE:300363, NAS:IFRX » details
Traded in other countries:PCJP.Germany,
Headquarter Location:USA
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB.

Top Ranked Articles about Abeona Therapeutics Inc

Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
Abeona Announces Participation at Upcoming Conferences
Factors of Influence in 2018, Key Indicators and Opportunity within AgroFresh Solutions, SMART SAND INC, Advantage Oil & Gas, Abeona Therapeutics, B. Riley Financial, and Audentes Therapeutics — New Research Emphasizes Economic Growth
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer
Andreas Halvorsen Takes Stake in Eidos Therapeutics Guru invests in newly public biopharmaceutical company
Viking Global Investors leader Andreas Halvorsen (Trades, Portfolio) disclosed he established a 5.5% stake in Eidos Therapeutics Inc. (NASDAQ:EIDX) on June 22. Read more...
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite Realty Group Trust, and Credicorp — Research Highlights Growth, Revenue, and Consolidated Results
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting

Ratios

vs
industry
vs
history
PB Ratio 3.71
ABEO's PB Ratio is ranked higher than
53% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ABEO: 3.71 )
Ranked among companies with meaningful PB Ratio only.
ABEO' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 3.62 Max: 55.44
Current: 3.71
1.16
55.44
PS Ratio 154.02
ABEO's PS Ratio is ranked lower than
90% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ABEO: 154.02 )
Ranked among companies with meaningful PS Ratio only.
ABEO' s PS Ratio Range Over the Past 10 Years
Min: 1.27  Med: 70.13 Max: 2680.72
Current: 154.02
1.27
2680.72
EV-to-EBIT -14.30
ABEO's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ABEO: -14.30 )
Ranked among companies with meaningful EV-to-EBIT only.
ABEO' s EV-to-EBIT Range Over the Past 10 Years
Min: -112.3  Med: -4.6 Max: 2
Current: -14.3
-112.3
2
EV-to-EBITDA -14.62
ABEO's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ABEO: -14.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABEO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -114.8  Med: -5 Max: 2
Current: -14.62
-114.8
2
EV-to-Revenue 126.06
ABEO's EV-to-Revenue is ranked lower than
85% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. ABEO: 126.06 )
Ranked among companies with meaningful EV-to-Revenue only.
ABEO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 77.4 Max: 5291.7
Current: 126.06
1.2
5291.7
Current Ratio 21.07
ABEO's Current Ratio is ranked higher than
92% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ABEO: 21.07 )
Ranked among companies with meaningful Current Ratio only.
ABEO' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.34 Max: 27.83
Current: 21.07
0.02
27.83
Quick Ratio 21.07
ABEO's Quick Ratio is ranked higher than
92% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ABEO: 21.07 )
Ranked among companies with meaningful Quick Ratio only.
ABEO' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.33 Max: 27.83
Current: 21.07
0.02
27.83
Days Sales Outstanding 4.45
ABEO's Days Sales Outstanding is ranked higher than
91% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. ABEO: 4.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.45  Med: 66.09 Max: 69.62
Current: 4.45
4.45
69.62

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -32.90
ABEO's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. ABEO: -32.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABEO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -328.9  Med: -17.7 Max: 0
Current: -32.9
-328.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.24
ABEO's Price-to-Net-Cash is ranked higher than
63% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. ABEO: 5.24 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABEO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.28  Med: 5.92 Max: 110.58
Current: 5.24
3.28
110.58
Price-to-Net-Current-Asset-Value 5.15
ABEO's Price-to-Net-Current-Asset-Value is ranked higher than
61% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. ABEO: 5.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABEO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.2  Med: 5.7 Max: 119.9
Current: 5.15
3.2
119.9
Price-to-Tangible-Book 4.79
ABEO's Price-to-Tangible-Book is ranked higher than
53% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ABEO: 4.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABEO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 5.38 Max: 1250
Current: 4.79
3.14
1250
Price-to-Intrinsic-Value-Projected-FCF 40.74
ABEO's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
91% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. ABEO: 40.74 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABEO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 9.33  Med: 18.74 Max: 51.61
Current: 40.74
9.33
51.61
Price-to-Median-PS-Value 2.19
ABEO's Price-to-Median-PS-Value is ranked lower than
88% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ABEO: 2.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABEO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.1 Max: 811.69
Current: 2.19
0.02
811.69
Earnings Yield (Greenblatt) % -6.99
ABEO's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ABEO: -6.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABEO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -438.8  Med: -20.5 Max: 78.5
Current: -6.99
-438.8
78.5

More Statistics

Revenue (TTM) (Mil) $3.85
EPS (TTM) $ -0.75
Beta0.87
Volatility43.73%
52-Week Range $10.50 - 22.75
Shares Outstanding (Mil)47.94

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 7 12 174 417
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.74 -0.70 1.88 5.74
EPS without NRI ($) -0.74 -0.70 1.88 5.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}